Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coya Therapeutics (COYA) EBITDA (2023 - 2025)

Historic EBITDA for Coya Therapeutics (COYA) over the last 3 years, with Q3 2025 value amounting to -$2.4 million.

  • Coya Therapeutics' EBITDA rose 4540.15% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.6 million, marking a year-over-year decrease of 8166.73%. This contributed to the annual value of -$17.2 million for FY2024, which is 11866.91% down from last year.
  • Coya Therapeutics' EBITDA amounted to -$2.4 million in Q3 2025, which was up 4540.15% from -$6.4 million recorded in Q2 2025.
  • In the past 5 years, Coya Therapeutics' EBITDA ranged from a high of $1.8 million in Q4 2023 and a low of -$7.7 million during Q1 2025
  • Moreover, its 3-year median value for EBITDA was -$3.6 million (2023), whereas its average is -$3.8 million.
  • As far as peak fluctuations go, Coya Therapeutics' EBITDA tumbled by 32357.11% in 2024, and later surged by 4540.15% in 2025.
  • Quarter analysis of 3 years shows Coya Therapeutics' EBITDA stood at $1.8 million in 2023, then plummeted by 323.57% to -$4.1 million in 2024, then surged by 40.44% to -$2.4 million in 2025.
  • Its last three reported values are -$2.4 million in Q3 2025, -$6.4 million for Q2 2025, and -$7.7 million during Q1 2025.